Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND HYDROCODONE BITARTRATE vs TRANXENE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.
Benzodiazepine; enhances GABA-A receptor activity by binding to benzodiazepine site, increasing chloride ion influx and neuronal hyperpolarization.
Moderate to moderately severe pain,Cough suppression (hydrocodone; off-label)
Anxiety disorders,Short-term relief of anxiety symptoms,Alcohol withdrawal syndrome,Adjunctive treatment for partial seizures
1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
7.5 mg to 15 mg orally 2 to 4 times daily; maximum dose 90 mg/day.
Acetaminophen: 2-3 hours in adults; prolonged in hepatic impairment (up to 5 hours). Hydrocodone: 3.8-4.5 hours (range 3-5 hours) in healthy adults; prolonged in elderly or hepatic/renal impairment. Clinical context: repeated dosing may require extended intervals in renal impairment.
Terminal elimination half-life of the active metabolite desmethyldiazepam is 30-200 hours (mean ~100 hours); parent drug clorazepate is rapidly hydrolyzed and has negligible half-life. Accumulation occurs with repeated dosing, leading to delayed peak effects and prolonged sedation.
Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; minor CYP2E1 oxidation to NAPQI (toxic metabolite). Hydrocodone: CYP3A4 and CYP2D6; N-demethylation to norhydrocodone; O-demethylation to hydromorphone (CYP2D6).
Hepatic via oxidative metabolism; primarily by CYP3A4 and CYP2C19 to active metabolite nordazepam, then to oxazepam and others. Also undergoes glucuronidation.
Acetaminophen: primarily renal excretion of conjugated metabolites (glucuronide and sulfate) with approximately 5% excreted unchanged. Hydrocodone: renal excretion as unchanged drug and metabolites (O-demethylated and N-demethylated); total renal excretion accounts for about 60-70% of dose (parent and metabolites). Biliary/fecal elimination is minimal.
Primarily renal (80-90% as conjugated metabolites, including oxazepam and desmethyldiazepam); biliary/fecal excretion accounts for <10%.
Acetaminophen: 10-25% bound, nonspecific binding to albumin. Hydrocodone: 25-50% bound, primarily to albumin and alpha-1-acid glycoprotein.
Clorazepate and desmethyldiazepam: 95-98% bound to albumin.
Acetaminophen: 0.8-1.0 L/kg, indicating distribution into total body water; clinically relevant for loading dose calculations. Hydrocodone: 3.0-4.0 L/kg, suggesting extensive tissue distribution; higher Vd may require higher loading doses but has no clinical target.
Clorazepate: 0.2-0.3 L/kg. Desmethyldiazepam: 0.5-1.5 L/kg (large Vd indicates extensive tissue distribution).
Acetaminophen: oral bioavailability 85-95% (first-pass metabolism minimal). Hydrocodone: oral bioavailability about 25-45% due to first-pass hepatic metabolism; significant interindividual variability.
Oral: nearly 100% (prodrug completely hydrolyzed in gastric acid to desmethyldiazepam). Intramuscular: erratic and incomplete (approximately 50-70% bioavailability due to variable absorption).
GFR 10-50 m L/min: administer every 6 hours; GFR <10 m L/min: administer every 8 hours; avoid in severe impairment due to acetaminophen metabolite accumulation.
GFR 10-50 m L/min: reduce dose by 25%; GFR <10 m L/min: reduce dose by 50% and use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: use with caution, avoid if possible, consider alternative therapy.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Dosing based on hydrocodone component: 0.1-0.2 mg/kg/dose every 4-6 hours; maximum daily acetaminophen limit: 75 mg/kg/day; not recommended for children <2 years.
Children 9-12 years: 7.5 mg orally twice daily; increase to 7.5 mg three times daily if needed. Not recommended under 9 years.
Initiate at lowest effective dose, typically 1 tablet (2.5-5 mg hydrocodone) every 6 hours; monitor for respiratory depression and acetaminophen toxicity; avoid in frail elderly with hepatic impairment.
Initiate at 3.75 mg orally 1 to 2 times daily; titrate slowly to avoid sedation and falls.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen; neonatal opioid withdrawal syndrome; interaction with alcohol; risk of medication errors.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve for patients with inadequate alternative treatment options.
Hepatotoxicity from acetaminophen overdose; respiratory depression; increased intracranial pressure; CNS depression; elderly/debilitated patients; renal impairment; opioid-induced hyperalgesia; serotonin syndrome; interaction with CNS depressants; risk of adrenal insufficiency; severe hypotension; use in patients with gastrointestinal obstruction; convulsion risk; severe hepatic impairment; urinary retention; acute abdominal conditions; hypothyroidism; prostatic hypertrophy; adrenocortical insufficiency; pregnancy/lactation; pediatric use; geriatric use; renal impairment; hepatic impairment.
Risk of dependence and withdrawal seizures with abrupt discontinuation,CNS depressant effects may impair driving or operating machinery,Use caution in hepatic impairment,Avoid in pregnancy (risk of neonatal withdrawal and floppy infant syndrome),Potential for anterograde amnesia,Elderly patients at increased risk for adverse effects
Hypersensitivity to acetaminophen or hydrocodone; significant respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected gastrointestinal obstruction; paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (acetaminophen toxicity risk); acute alcoholism.
Hypersensitivity to clorazepate or other benzodiazepines,Acute narrow-angle glaucoma,Severe hepatic impairment,Pregnancy (especially first trimester),Breastfeeding,Concomitant use with opioids unless alternative treatments are inadequate
Avoid alcohol consumption during therapy; ethanol increases acetaminophen hepatotoxicity risk and enhances CNS depression. Grapefruit juice may inhibit CYP2D6 (minor effect) but no significant clinical interaction. No other specific food restrictions.
No specific food interactions. Grapefruit juice does not significantly affect metabolism. Fatty meals may delay absorption of oral clorazepate, but overall bioavailability not affected.
First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital malformations (e.g., neural tube defects, cleft palate) with first trimester opioid use, but absolute risk is low. Second trimester: Low risk as above. Third trimester: Prolonged use of hydrocodone can cause neonatal opioid withdrawal syndrome (NOWS); acetaminophen is safe. Use only if benefit outweighs risk.
FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip/palate, when used during the first trimester. Second and third trimesters: Chronic use may lead to physical dependence and withdrawal symptoms in the neonate, including floppy infant syndrome, respiratory depression, and feeding difficulties. Late pregnancy or near delivery: Risk of neonatal sedation, hypotonia, and withdrawal.
Acetaminophen excretion in breast milk is low (M/P ratio ~0.9). Hydrocodone is excreted in small amounts (M/P ratio ~2.1). The relative infant dose is estimated to be 2.5-3.5% of maternal weight-adjusted dose for hydrocodone. Monitor infant for sedation and respiratory depression. Consider benefit to mother and potential neonatal opioid withdrawal if used chronically.
Excreted in human milk. M/P ratio not established. Case reports indicate low milk levels (approx 4-10% of maternal weight-adjusted dose) but infant accumulation possible due to long half-life. Benefits of breastfeeding should be weighed against potential risks of sedation and poor feeding in the infant. Monitor infant for drowsiness, poor suckling, and weight loss.
During pregnancy, increased plasma volume and enhanced hepatic clearance may reduce serum concentrations of both drugs. However, dosing adjustments are not routinely recommended due to risk of undertreatment. Use the lowest effective dose of hydrocodone for the shortest duration. For acetaminophen, maximum daily dose should not exceed 3000 mg to avoid hepatotoxicity.
Due to increased volume of distribution and enhanced clearance, higher doses may be required during pregnancy to maintain efficacy, especially in the second and third trimesters. However, dose adjustment should be individualized and cautious because of potential fetal risks. Use the lowest effective dose for the shortest duration. Avoid high doses near term.
Acetaminophen-hydrocodone is contraindicated in severe respiratory depression, acute or severe bronchial asthma, and known hypersensitivity. Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid use with other acetaminophen-containing products to prevent hepatotoxicity. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; CYP2D6 ultrarapid metabolizers may experience toxicity. Use with caution in patients with head injury, increased intracranial pressure, or severe hepatic impairment. Naloxone is the reversal agent for opioid effects; acetylcysteine for acetaminophen overdose.
TRANXENE (clorazepate) is a benzodiazepine prodrug that is decarboxylated in the stomach to the active metabolite N-desmethyldiazepam. Onset of action is relatively slow (1-2 hours) compared to diazepam. Due to its long half-life (up to 100 hours for active metabolite), accumulation is possible in elderly or hepatically impaired patients. Avoid in narrow-angle glaucoma. Abrupt discontinuation may precipitate withdrawal seizures.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not exceed 4000 mg of acetaminophen per day from all sources; check labels of other medications.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Store securely out of reach of others, especially children, as misuse can cause overdose and death.,Do not stop abruptly; withdrawal may occur. Taper under medical supervision.,Contact emergency if you experience trouble breathing, extreme drowsiness, or signs of allergic reaction.,Report any history of substance abuse, as this medication has abuse potential.
Do not stop taking suddenly; taper under medical supervision to avoid withdrawal symptoms.,Avoid alcohol and other CNS depressants (e.g., opioids, sleep aids) as they increase sedation and respiratory depression risk.,May cause drowsiness, dizziness; avoid driving or operating machinery until effect is known.,Take with or without food. Do not crush or chew extended-release capsules.,Inform doctor if you have a history of substance abuse, liver disease, or glaucoma.,Use caution in elderly patients due to increased risk of falls and cognitive impairment.,Notify doctor immediately if you experience suicidal thoughts, unusual mood changes, or allergic reactions.
"Hydrocodone, an opioid agonist, and scopolamine, an anticholinergic agent, both exhibit central nervous system (CNS) depressant effects. When co-administered, their combined activity can lead to additive CNS depression, resulting in enhanced sedation, respiratory depression, and cognitive impairment. This interaction may also increase the risk of constipation and urinary retention due to additive anticholinergic effects from both drugs."
"Pargyline, a monoamine oxidase inhibitor (MAOI), irreversibly inhibits the metabolism of amines, leading to increased intraneuronal stores of norepinephrine. Hydrocodone, a semisynthetic opioid, can release these stored catecholamines, potentially causing a hypertensive crisis, serotonin syndrome, or CNS excitation. Coadministration may also result in excessive sedation and respiratory depression due to additive CNS depressant effects, requiring immediate clinical attention."
"Hydrocodone, an opioid agonist, and oxprenolol, a non-selective beta-adrenoceptor antagonist, are both central nervous system (CNS) depressants. Their combined use can lead to additive CNS depression, resulting in excessive sedation, respiratory depression, hypotension, and bradycardia. This interaction is particularly dangerous in patients with compromised cardiac or respiratory function, potentially leading to coma or death."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND HYDROCODONE BITARTRATE vs TRANXENE, answered by our medical review team.
ACETAMINOPHEN AND HYDROCODONE BITARTRATE is a Opioid Agonist that works by Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.. TRANXENE is a Benzodiazepine Anxiolytic that works by Benzodiazepine; enhances GABA-A receptor activity by binding to benzodiazepine site, increasing chloride ion influx and neuronal hyperpolarization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND HYDROCODONE BITARTRATE and TRANXENE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND HYDROCODONE BITARTRATE is: 1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. The standard adult dose of TRANXENE is: 7.5 mg to 15 mg orally 2 to 4 times daily; maximum dose 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND HYDROCODONE BITARTRATE and TRANXENE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is classified as Category D/X. First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital. TRANXENE is classified as Category C. FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip/palate, when used during the first trimester. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.